Skip to Main Content

Paper Details

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
Blood Adv
10
2023
Author NameAffiliation
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Farhad RavandiThe University of Texas MD Anderson Cancer Center
  • 1 - 5

Datasets

Release 1.2